Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0885066621997365 http://scihub22266oqcxt.onion/10.1177/0885066621997365 33663244!8145440!33663244     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Intensive+Care+Med 2021 ; 36 (6): 681-688 Nephropedia Template TP {{tp|p=33663244|t=2021. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS |pdf=|usr=}}{{33663244}} gab.com Text Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS JO: J Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=33663244 #FOAvip BACKGROUND: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times. RESULT: Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 +/- 0.2 versus 2.8 +/- 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge. CONCLUSION: MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population. Twit Text FOAVip Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS ????J Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=33663244 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33663244 #FOAvip English Wikipedia <ref>{{Cite pmid|33663244}}</ref> Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS #MMPMID33663244 Haberle H; Magunia H; Lang P; Gloeckner H; Korner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V J Intensive Care Med 2021[Jun]; 36 (6): 681-688 PMID33663244show ga BACKGROUND: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times. RESULT: Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 +/- 0.2 versus 2.8 +/- 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge. CONCLUSION: MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population. |*Critical Care[MESH] |*Mesenchymal Stem Cell Transplantation[MESH] |Adult[MESH] |Aged[MESH] |COVID-19/*complications/mortality/*therapy[MESH] |Cohort Studies[MESH] |Female[MESH] |Germany[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Respiration, Artificial[MESH] |Respiratory Distress Syndrome/mortality/*therapy/*virology[MESH] |Survival Rate[MESH]Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS (epmc).pdf DeepDyve Pubget Overpricing